Funding for this research was provided by:
Alexion, AstraZeneca Rare Disease
Received: 19 October 2022
Accepted: 28 June 2023
First Online: 5 July 2023
: The International PNH Registry was approved by the institutional review boards (or equivalent) of participating centers, and all patients provided written informed consent before inclusion.
: Not applicable.
: D. Cella is the President of FACIT.org and has received research support and consulting fees from Alexion, AstraZeneca Rare Disease. P. Johansson has no conflicts of interest to disclose. Y. Ueda has served as a consultant and received honoraria from Alexion, AstraZeneca Rare Disease, Sanofi, Chugai, and Novartis, and research funding from Chugai. P. Gustovic, A. Wang, and AS Patel are employees of Alexion, AstraZeneca Rare Disease. I Tomazos was an employee of Alexion, AstraZeneca Rare Disease at the time of the study. H Schrezenmeier has received travel support, honoraria, and research support (to institution) from Alexion, AstraZeneca Rare Disease, and Novartis, and honoraria (to University of Ulm) from Roche, Apellis, and Sanofi.